出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/07/15 21:15:51」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Review article: description and management of fatigue in inflammatory bowel disease.
  • Czuber-Dochan W, Ream E, Norton C.SourceKing's College London, Florence Nightingale School of Nursing & Midwifery, London, UK.
  • Alimentary pharmacology & therapeutics.Aliment Pharmacol Ther.2013 Mar;37(5):505-16. doi: 10.1111/apt.12205. Epub 2013 Jan 13.
  • BACKGROUND: Fatigue is a common and leading concern for patients with inflammatory bowel disease (IBD). It is managed inadequately in IBD, and there is little evidence to support interventions.AIM: To examine patients' experience of and factors contributing to IBD-fatigue, and to appraise its manage
  • PMID 23311461
  • Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
  • Baert F, Glorieus E, Reenaers C, D'Haens G, Peeters H, Franchimont D, Dewit O, Caenepeel P, Louis E, Van Assche G; for BIRD (Belgian IBD Research and Development).SourceDepartment of Internal Medicine, H.-Hart ziekenhuis Roeselare-Menen, Belgium. Electronic address:
  • Journal of Crohn's & colitis.J Crohns Colitis.2013 Mar 1;7(2):154-60. doi: 10.1016/j.crohns.2012.03.018. Epub 2012 Apr 24.
  • BACKGROUND AND AIMS: Adalimumab is efficacious in inducing and maintaining remission in Crohn's disease but dose escalation is needed in 30-40% after 1year. Attempts for dose de-escalation have not been studied. This study aimed to assess the need for, predictors, and outcome of dose escalation and
  • PMID 22537637
  • Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.
  • McDermott E, Murphy S, Keegan D, O'Donoghue D, Mulcahy H, Doherty G.SourceCentre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. Electronic address:
  • Journal of Crohn's & colitis.J Crohns Colitis.2013 Mar 1;7(2):150-3. doi: 10.1016/j.crohns.2012.03.016. Epub 2012 Apr 18.
  • INTRODUCTION: Adalimumab is a recombinant human IgG1 monoclonal antibody to TNF-alpha. There are limited data with regard to its efficacy in ulcerative colitis. We report experience of adalimumab in ulcerative colitis in a single centre with a focus on the ability of this agent to maintain response
  • PMID 22520592


  • アダリムマブ投与中にHBV-DNAが陽転化した尋常性乾癬の1例 (特集 角化症・炎症性角化症)
  • 長田 麻友美,柴田 彩,鎌田 昌洋 [他]
  • 皮膚科の臨床 56(8), 1111-1114, 2014-08
  • NAID 40020180361
  • 症例報告 アダリムマブ導入後に高血圧の改善がみられた尋常性乾癬の1例
  • 石井 健,西村 千尋,五味 博子 [他]
  • 臨床皮膚科 = Japanese journal of clinical dermatology 68(6), 403-406, 2014-05
  • NAID 40020099340
  • Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report
  • Takazono Takahiro,Nakamura Shigeki,Imamura Yoshifumi,Miyazaki Taiga,Izumikawa Koichi,Kakeya Hiroshi,Yanagihara Katsunori,Kohno Shigeru
  • BMC Infectious Diseases 14(1), 114, 2014-02-28
  • adalimumab was therefore administered in combination with oral glucocorticoids. … Treatment with 40 mg of adalimumab led to rapid improvement of his clinical manifestations. … However, the patient developed an intermittent high fever and productive cough 15 months after starting adalimumab treatment. …
  • NAID 120005438869


Learn more about HUMIRA (adalimumab), including dosing, safety and side effects, benefits, and risks. The official website from AbbVie Inc. ... HUMIRA Use 1 HUMIRA is a prescription medicine used to treat adults with moderate to ...
クローン病で国内で申請されてヒュミラ (Adalimumab)とは完全にヒト化された抗TNF-α抗体の製剤。商品名ヒュミラである。海外商品名HUMIRA 現在はクローン病で保険適用,潰瘍性大腸炎では治験段階となっている.


Catalog » Adalimumab 5266Bindung von TNF-alpha durch Adalimumab als  aviso referencias adalimumab adalimumab Factor-Alpha Therapies: AdalimumabAdalimumab (Адалимумаб)Nombre: Adalimumab